11C-Metomidate PET Scan for Adrenal Imaging
11C-metomidate PET/CT is a specialized second-line functional imaging modality that specifically identifies adrenocortical tissue by binding to 11β-hydroxylase enzymes, primarily used to distinguish adrenocortical from non-adrenocortical masses and to lateralize aldosterone-producing adenomas in primary aldosteronism when adrenal vein sampling is equivocal, failed, or contraindicated.
Primary Indications
11C-metomidate PET is not a first-line test - CT and MRI remain the primary imaging modalities for adrenal lesions 1. This specialized PET scan is reserved for specific clinical scenarios:
1. Characterization of Indeterminate Adrenal Masses
- When CT (attenuation >10 HU, inadequate washout) and MRI (no signal loss on chemical shift imaging) cannot definitively characterize a lesion as benign
- Distinguishing adrenocortical from non-adrenocortical lesions (e.g., metastases, pheochromocytoma) with 89% sensitivity and 96% specificity 2
- Particularly valuable in patients with known extra-adrenal malignancy where determining if an adrenal mass is a metastasis versus an incidental adenoma changes management 3
2. Primary Aldosteronism Lateralization
- As an alternative or adjunct to adrenal vein sampling (AVS), which is technically challenging, invasive, and has limited availability 4, 5
- Recent prospective data shows 11C-metomidate is noninferior to AVS for predicting surgical outcomes, with 71.3% accuracy for biochemical success 5
- Particularly useful when AVS is equivocal, technically failed, or contraindicated 4
3. Detection of Adrenocortical Carcinoma Metastases
- Can visualize metastatic adrenocortical carcinoma lesions due to retained 11β-hydroxylase expression 3
Patient Preparation
The provided evidence does not detail specific patient preparation protocols. Based on standard PET imaging principles:
- No specific dietary restrictions are typically required (unlike FDG-PET)
- Patients should avoid medications that interfere with adrenal steroidogenesis if possible, though specific guidance is not provided in the literature
- Standard PET contraindications apply (pregnancy, inability to lie still)
Imaging Protocol
Technical Specifications
- Tracer: 11C-metomidate binds with high specificity to CYP11B enzymes (11β-hydroxylase and aldosterone synthase) exclusively expressed in adrenocortical cells 3, 6
- Imaging modality: PET/CT (combined anatomic and functional imaging)
- Radiation exposure: Higher than conventional CT due to PET component 1
- Requires specialist expertise and is available only at specialized centers 1
Alternative Tracer
- [18F]CETO (para-chloro-2-[18F]fluoroethyletomidate): A longer-half-life analogue showing excellent agreement with 11C-metomidate (κ = 0.85) in 29 of 31 patients 5
- The longer half-life of 18F (110 minutes vs 20 minutes for 11C) offers logistical advantages for centers without on-site cyclotrons
Interpretation Criteria
Quantitative Analysis
- Standardized Uptake Values (SUV) are measured to quantify tracer uptake 2, 6
- Normal adrenocortical tissue shows physiologic uptake bilaterally
- Pathological adrenocortical tissue (lesions >1-1.5 cm) can be differentiated from normal tissue by SUV measurements 2
Specific Findings by Pathology
Positive (High Uptake):
- Adrenocortical adenomas: Median SUV 18.6 6
- Aldosterone-producing adenomas: Higher SUV values, with significantly higher SUV ratios between tumor and contralateral gland 2
- Cortisol-producing adenomas: Also show elevated SUV ratios 2
- Adrenocortical carcinoma: Uptake typically in the lower range but still positive 2, 6
- Adrenocortical hyperplasia: Positive uptake 2
Negative (No/Minimal Uptake):
- Pheochromocytomas: Median SUV 1.9 - all are metomidate-negative 2, 6
- Adrenal metastases: No uptake (non-adrenocortical origin) 2, 6
- Non-adrenal masses: No uptake 2
Key Interpretation Principle
11C-metomidate distinguishes adrenocortical from non-adrenocortical lesions with high accuracy but cannot reliably differentiate benign from malignant adrenocortical tissue 6. For malignancy assessment, FDG-PET remains superior 1, 6.
Primary Aldosteronism Lateralization
- Unilateral increased uptake suggests lateralized aldosterone production
- Interpretation should be integrated with adrenal CT findings and clinical context 4
- In the prospective trial, 52.7% of patients were predicted to have unilateral PA by 11C-metomidate versus 46.2% by AVS 5
Important Caveats and Pitfalls
Limitations
- Cannot definitively distinguish benign from malignant adrenocortical lesions - both can show uptake 6
- Limited sensitivity for lesions <1 cm (similar to FDG-PET) 1
- Requires specialized centers with PET capability and expertise 1
- Higher radiation exposure than CT alone 1
- Short half-life of 11C (20 minutes) requires on-site cyclotron unless using 18F-labeled alternatives 5
Complementary Role with FDG-PET
- For suspected malignancy: FDG-PET is superior for identifying malignant lesions 6
- For adrenocortical characterization: 11C-metomidate is superior 6
- In practice, both tracers may provide complementary information
Unique Finding in Primary Aldosteronism
Unlike Cushing's syndrome where contralateral adrenal suppression occurs, 11β-hydroxylase expression is NOT suppressed in the contralateral gland in primary aldosteronism 6. This is an important physiologic distinction observed on metomidate imaging.
Clinical Decision Algorithm
- First-line: Dedicated adrenal CT (noncontrast attenuation, washout analysis) or MRI (chemical shift imaging) 1
- If indeterminate mass in patient with extra-adrenal malignancy: Consider FDG-PET first to assess for metastasis 1
- If indeterminate mass requires adrenocortical confirmation: 11C-metomidate PET/CT 3, 2
- For primary aldosteronism lateralization: AVS remains gold standard, but 11C-metomidate is a noninferior alternative when AVS is unavailable, failed, or equivocal 5